fda novavax - Search News

Order byBest matchMost fresh

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

· 2d · on MSN

Novavax Stock Soars on FDA Approval for New COVID-19 Vaccine

Clinical Advisor · 13h

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

· 1d

F.D.A. Poised to Restrict Access to Covid Vaccines

The Food and Drug Administration will permit Covid vaccines for adults over 65 and those with certain medical conditions in the fall, according to new regulatory standards detailed on Tuesday by agen...

· 1d

FDA tightens requirements for COVID vaccine, adding trials for healthy adults

· 1d

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved

· 1d

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

Millions of healthy adults and kids will likely lose access to updated vaccines under the new criteria.

· 12h

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

· 1d

FDA sets new COVID booster guidelines for healthy adults under 65

1don MSN

FDA sets new COVID booster guidelines for healthy adults under 65

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

10hon MSN

FDA may limit future COVID-19 boosters to seniors, those at higher risk for complications

US Food and Drug Administration officials are changing the agency's standards for updated COVID-19 booster shots with focus on seniors, high-risk persons.

2don MSN

RFK Jr. pledged not to upend US vaccine system, but big changes are underway

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.